Revvity (NYSE:RVTY) Issues Earnings Results

Revvity (NYSE:RVTY) issued its earnings results on Monday. The company reported $1.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.12 by $0.10, RTT News reports. The company had revenue of $691.70 million during the quarter, compared to analysts’ expectations of $690.33 million. Revvity had a return on equity of 7.35% and a net margin of 6.26%. The firm’s quarterly revenue was down 2.5% on a year-over-year basis. During the same period in the prior year, the business earned $1.21 EPS. Revvity updated its FY 2024 guidance to 4.700-4.800 EPS and its FY24 guidance to $4.70-4.80 EPS.

Revvity Trading Up 1.3 %

Shares of RVTY opened at $127.24 on Wednesday. Revvity has a twelve month low of $79.50 and a twelve month high of $127.88. The company has a current ratio of 2.23, a quick ratio of 1.92 and a debt-to-equity ratio of 0.40. The firm has a market capitalization of $15.70 billion, a P/E ratio of 105.16, a PEG ratio of 3.27 and a beta of 1.05. The firm’s 50-day moving average is $109.37 and its two-hundred day moving average is $106.68.

Revvity Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, November 8th. Investors of record on Friday, October 18th will be paid a $0.07 dividend. This represents a $0.28 annualized dividend and a dividend yield of 0.22%. The ex-dividend date is Friday, October 18th. Revvity’s dividend payout ratio (DPR) is 23.14%.

Analyst Upgrades and Downgrades

A number of brokerages have commented on RVTY. JPMorgan Chase & Co. lifted their target price on shares of Revvity from $105.00 to $120.00 and gave the stock a “neutral” rating in a research note on Tuesday. SVB Leerink began coverage on shares of Revvity in a research report on Monday, July 8th. They set an “outperform” rating and a $125.00 price objective for the company. Leerink Partnrs raised shares of Revvity to a “strong-buy” rating in a report on Monday, July 8th. Bank of America raised their price objective on shares of Revvity from $118.00 to $127.00 and gave the company a “neutral” rating in a report on Tuesday. Finally, Robert W. Baird upped their price objective on Revvity from $126.00 to $127.00 and gave the stock an “outperform” rating in a research report on Tuesday, April 30th. Eight equities research analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $123.81.

Insider Transactions at Revvity

In related news, insider Joel S. Goldberg sold 4,000 shares of the stock in a transaction dated Friday, June 7th. The shares were sold at an average price of $110.46, for a total value of $441,840.00. Following the sale, the insider now directly owns 36,900 shares of the company’s stock, valued at approximately $4,075,974. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Corporate insiders own 0.60% of the company’s stock.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.